Incannex’s IHL-42X Lowered AHI, ODI in Obstructive Sleep Apnea Phase 2 Trial

Incannex Healthcare Ltd, a clinical-stage pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies, has completed analysis of data from the phase 2 proof-of-concept clinical trial investigating IHL-42X for treatment of obstructive sleep apnea (OSA). IHL-42X reduced apnea-hypopnea index (AHI), improved patient reported sleep quality, and was well tolerated. The clinical trial assessed … Read more